Sprint Bioscience is a pharmaceutical corporation specialized in the advancement of medications for cancer. Additionally, we have an initiative dedicated to type 2 diabetes within our project portfolio. Established in 2009, the company was co-founded by an enterprising group of five individuals, four from the Swedish pharmaceutical sector (Anders Åberg, Jessica Martinsson, Kenth Hallberg, and Martin Andersson) and one from academic research (Professor Pär Nordlund). The objective is to establish a Swedish enduring pharmaceutical organization excelling in preclinical drug development. The founders are motivated by the opportunity to create an impact and to formulate medications that can be introduced to the market.
Sprint Bioscience
Headquarters
Sweden